Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool April 28, 2011 Brian Orelli	Buying Royalty Streams on the Cheap If management can't do it, PDL Biopharma's investors are in trouble. The trick is to find patents that are secure and a royalty stream that's predictable.
The Motley Fool July 9, 2004 Charly Travers	Protein Design Labs' Windfall Royalties from Genentech could mean big things for PDL.
The Motley Fool November 12, 2007 Brian Lawler	What's New at PDL BioPharma? The past few volatile months are reflected in the third-quarter results from PDL BioPharma. The future, however, may be smoother. Investors, take note.
The Motley Fool December 13, 2004 Charly Travers	PDL Rakes It In A robust revenue stream combined with an exciting drug pipeline is this biotech's recipe for success.
The Motley Fool July 27, 2004 Charly Travers	Cash Concerns at Vertex New royalties might not help offset losses at the pharmaceutical, so it's time to look at the drug pipeline.
The Motley Fool April 14, 2008 Brian Lawler	PDL BioPharma's Split Decision PDL BioPharma is finally taking further steps to try to realize better value for the different parts of its business.
The Motley Fool October 26, 2011 Brian Orelli	Momenta Stopped. Again. Oh, no - an authorized generic gets launched.
The Motley Fool August 4, 2004 Charly Travers	Labs' Report Offers Mixed Results TProtein Design Labs' royalty intake looks great, but its drug development does not.
The Motley Fool July 14, 2005 Charly Travers	Dueling Fools: Protein Design Labs Bull Protein Design Labs is a great company for biotech investors. It has a diverse and growing revenue stream, will turn cash-flow positive next year, and has some potential winners in its pipeline to increase the company's value for long-term-minded shareholders.
The Motley Fool July 21, 2011 Brian Orelli	Keep an Eye on Biotech Partners' Earnings Novartis' earnings are important for small biotechs Momenta and Vanda.
The Motley Fool July 30, 2007 Brian Orelli	Is Par Pharmaceutical Settling for Less? The generic drugmaker avoids going to court in some recent cases. Patent lawyers are the lifeblood of a generic drugmaker, and investors should want them to act as aggressively as possible so that Par can expand its product line.
The Motley Fool November 2, 2004 Charly Travers	Just the Medicine for PDL Losses are shrinking as drug royalties spur strong revenue growth.
Pharmaceutical Executive July 1, 2011 Todd C. Davis	Seeing the Fire Behind the Smoke While crafting license agreements involves all of the tactical tradeoffs expected in a negotiating dynamic, one should try to pay attention to these 10 licensing pitfalls.
Chemistry World February 27, 2013 Andrew Turley	Talk of a $6.6bn deal for Elan Irish drug maker Elan has been surprised by a potential $6.6 billion offer being mooted by investment firm Royalty Pharma.
The Motley Fool April 14, 2011 Frank Vinluan	Biogen Idec Inks Biotech Blood Products Research Deal With Amunix The exclusive, worldwide research collaboration agreement calls for both companies to jointly conduct preclinical research.
The Motley Fool November 26, 2011 Stephanie Baum	Pozen Inks $75 Million Royalty Deal for Treximet The pharma sells U.S. rights for the migraine drug to Canada's national pension fund.
The Motley Fool October 16, 2006 Brian Lawler	Negative Revenue Surprise From Aspreva Shares of the pharmaceutical dropped last week when the company announced it won't meet analysts' guidance for third-quarter revenue.
Pharmaceutical Executive February 1, 2009 Flamenbaum et al.	Stream Power Convert future revenue into present value with alternative approaches to access capital.
The Motley Fool November 20, 2008 Brian Orelli	Sanofi Breathing Easier Drugmaker Sanofi-Aventis settles a few patent disputes with generic-drugmaker nemeses.
The Motley Fool October 31, 2011 Brian Orelli	5 One-Drug Wonders Going for No. 2 Here are five drugmakers hoping not to become one-hit wonders: Vertex... Onyx... Momenta... Elan... Dendreon...
The Motley Fool December 7, 2011 Dan Caplinger	Has PDL BioPharma Become the Perfect Stock? Having moved from special dividends to a pure regular-dividend payout has improved income visibility for shareholders.
Pharmaceutical Executive September 1, 2006	Finance: Good Alternatives With more ways to raise cash, biotechs with hot products can extend their independence.
The Motley Fool March 15, 2005 Charly Travers	PDL Eyeing Up Profits A timely acquisition is paying off for this drug maker. Investors, take note.
The Motley Fool July 15, 2011 Brian Orelli	Vical Transplants Some Firepower A licensing deal with Astellas gives the company a shot in the arm.
The Motley Fool May 31, 2011 David Williamson	Roundtable: The World's Best Biotechs Motley Fool analysts choose these as their favorite biotech stocks: Aeterna Zentaris... Seattle Genetics... BioMarin Pharmaceutical... Amarin...
The Motley Fool July 30, 2007 Brian Orelli	Palomar Plummets In the second quarter, cosmetic-laser maker Palomar Medical Technology had a stellar performance in the former, but investors couldn't look past the lack of royalty payments.
The Motley Fool March 5, 2008 Brian Lawler	PDL Taken Off the Block Yesterday, PDL BioPharma announced that it had failed to find an acquirer; instead, it will launch another round of restructuring.
The Motley Fool November 13, 2009 Brian Orelli	Abbott: Brave or Stupid? Abbott Labs announces the acquisition of PanGenetics' pain drug PG110, which is still in phase 1 trials.
The Motley Fool December 20, 2007 Brian Orelli	2007: The Year Pharma Fell in Love With Biologics The reason for pharma's newfound infatuation for biotech is quite clear. Many pharmaceutical companies are facing a patent cliff in the coming years, and they need to replace their blockbusters with something.
The Motley Fool August 29, 2008 Brian Lawler	Will Biopharma Acquisitions Never Cease? In both the size and quantity of proposed deals, the past 24 months have been busier than ever for biopharma dealmakers. What's behind all this activity?
The Motley Fool May 26, 2009 Brian Orelli	Buy Now! It Might Get Bought! Clinical trial results and FDA approvals ultimately drive any increase in drugmakers' value. That's what pharmaceutical investors should focus on. The potential for an acquisition should be nothing more than icing on the cake.
The Motley Fool October 31, 2006 Brian Lawler	A Biotech Frankenstock Investors, here is the perfect biotechnology beast. Cephalon... Roche... Exelixis... etc.
The Motley Fool February 13, 2006 Brian Gorman	Albany Molecular's Royalty Squeeze Declining royalty revenue is likely to keep buffeting the contract services provider. Investors, take note.
The Motley Fool December 12, 2008 Brian Orelli	An EXELent Drug Deal Exelixis picks up $195 million in cash in a licensing deal with Bristol-Myers Squibb.
The Motley Fool December 31, 2007 Brian Lawler	The Biotech Year in Review Following the biotech sector is never dull, and 2007 was no exception to the rule. Let's take a look at the highlights and lowlights of 2007.
The Motley Fool May 8, 2009 Brian Orelli	Growth in All the Wrong Places The potential of Onyx's tumor drug Nexavar will always be a major component in the company's value, but investors should watch the growth in current indications -- and where it's coming from -- in case the additional indications don't pan out.
The Motley Fool January 12, 2006 Stephen D. Simpson	Forest Keeps Reloading An agreement with Mylan Labs gives Forest access to a drug that could be launched in 2006. Investors, take note.
The Motley Fool October 22, 2009 Brian Orelli	Elan's Headed in the Right Direction Revenue up, costs down. It's a good direction for Elan to take, even if the company's final earnings number was slightly inflated.
The Motley Fool October 25, 2007 Brian Lawler	Flamel Gets Upbeat News About Coreg Flamel Technologies is earning more than had been calculated from its lead drug, but the company still isn't profitable. Investors, take note.
The Motley Fool May 21, 2010 Brian Orelli	And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too.
The Motley Fool February 19, 2009 Brian Orelli	BioMarin Is Off Track Shares of BioMarin Pharmaceutical, a darling of the drug world whose shares more than doubled in 2007, come crashing down because the growth of years past seems to be waning.
The Motley Fool December 20, 2004 Brian Gorman	Cambridge Antibody's Underdog Story Cambridge Antibody's legal success against Abbott Laboratories is a sign of the biotech industry's continued maturation. Cambridge Antibody's stock rocketed 14% on the news of its win.
The Motley Fool June 3, 2010 Brian Orelli	When All Else Fails, Sue Your Competitors Biogen thinks its patent covers its competitors' drugs in addition to Avonex and has filed a lawsuit demanding royalties from its competitors.
The Motley Fool July 10, 2009 Brian Orelli	Vertex Pulls a Wimpy After four follow-on stock offerings in the last three years, Vertex Pharmaceuticals finally has a plan to raise some cash that won't dilute its shareholders.
Bio-IT World June 17, 2004 Stephanie McRae	Expatriate Your Patents Intellectual property rights, especially patents, are often the principal source of value and revenue for biotechnology companies. You can save a boatload of tax money shipping your IP rights overseas.
The Motley Fool March 9, 2011 Brian Orelli	Slicing and Dicing Your Way through Drug Development The drug developer announces that it licensed the Japanese rights to perifosine, its lead cancer drug, to Yakult Honsha.
The Motley Fool April 9, 2008 Brian Orelli	Repligen Gets a Surprise Infusion of Cash Bristol-Myers Squibb agrees to pay Repligen royalties in their patent-infringement lawsuit.
The Motley Fool September 11, 2007 Brian Lawler	Where Momenta Stands Momenta Pharmaceuticals updates investors as to the status of drugs in its pipeline. Until the FDA makes up its mind on its lead drug, an anticoagulant, it's anyone's guess as to what the value of the pipeline is. Investors should take note.
The Motley Fool July 27, 2006 Brian Lawler	Aspreva's One-Drug Wonder With rapidly growing royalties from CellCept, and the potential to expand the drug into new indications, shares of Aspreva are attractive at current levels, as long as the company does not make any bad acquisitions with its cash hoard.
Home Theater April 30, 2007	Congress May Rescue Net Radio A bill surfaced last week that would reverse the recent royalty rate hike that net radio outfits say would have doomed them to extinction.